Shots:

• Progenics to receive royalties on sales of 1404 in EU. ROTOP to get an exclusive license to develop & commercialize 1404 in EU and is also responsible for regulatory approvals
• The focus of the agreement is to expand ROTOP’s PSMA targeted prostate cancer portfolio and to accelerate the development of 1404 for treating prostate cancer in Europe
• Progenic’s 1404 is a prostate specific membrane antigen (PSMA) targeting SPECT/CT imaging agent labeled with technetium-99m- designed for the detection of primary and metastatic prostate cancer with its expected clinical trials onset in H1’20

Ref: Progenics | Image: Annual Reports